The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward

TY - JOUR

T1 - The role of high-field magnetic resonance imaging in parkinsonian disorders

T2 - Pushing the boundaries forward

AU - Lehericy, Stéphane

AU - Vaillancourt, David E.

AU - Seppi, Klaus

AU - Monchi, Oury

AU - Rektorova, Irena

AU - Antonini, Angelo

AU - McKeown, Martin J.

AU - Masellis, Mario

AU - Berg, Daniela

AU - Rowe, James B.

AU - Lewis, Simon J.G.

AU - Williams-Gray, Caroline H.

AU - Tessitore, Alessandro

AU - Siebner, Hartwig R.

AU - on behalf of the International Parkinson and Movement Disorder Society (IPMDS)-Neuroimaging Study Group

PY - 2017/4

Y1 - 2017/4

N2 - Historically, magnetic resonance imaging (MRI) has contributed little to the study of Parkinson's disease (PD), but modern MRI approaches have unveiled several complementary markers that are useful for research and clinical applications. Iron- and neuromelanin-sensitive MRI detect qualitative changes in the substantia nigra. Quantitative MRI markers can be derived from diffusion weighted and iron-sensitive imaging or volumetry. Functional brain alterations at rest or during task performance have been captured with functional and arterial spin labeling perfusion MRI. These markers are useful for the diagnosis of PD and atypical parkinsonism, to track disease progression from the premotor stages of these diseases and to better understand the neurobiological basis of clinical deficits. A current research goal using MRI is to generate time-dependent models of the evolution of PD biomarkers that can help understand neurodegeneration and provide reliable markers for therapeutic trials. This article reviews recent advances in MRI biomarker research at high-field (3T) and ultra high field-imaging (7T) in PD and atypical parkinsonism.

AB - Historically, magnetic resonance imaging (MRI) has contributed little to the study of Parkinson's disease (PD), but modern MRI approaches have unveiled several complementary markers that are useful for research and clinical applications. Iron- and neuromelanin-sensitive MRI detect qualitative changes in the substantia nigra. Quantitative MRI markers can be derived from diffusion weighted and iron-sensitive imaging or volumetry. Functional brain alterations at rest or during task performance have been captured with functional and arterial spin labeling perfusion MRI. These markers are useful for the diagnosis of PD and atypical parkinsonism, to track disease progression from the premotor stages of these diseases and to better understand the neurobiological basis of clinical deficits. A current research goal using MRI is to generate time-dependent models of the evolution of PD biomarkers that can help understand neurodegeneration and provide reliable markers for therapeutic trials. This article reviews recent advances in MRI biomarker research at high-field (3T) and ultra high field-imaging (7T) in PD and atypical parkinsonism.

KW - 7T

KW - atypical parkinsonism

KW - diffusion MRI

KW - fMRI

KW - iron

KW - MRI

KW - neuromelanin

KW - Parkinson's disease

KW - resting state fMRI

U2 - 10.1002/mds.26968

DO - 10.1002/mds.26968

M3 - Review

C2 - 28370449

AN - SCOPUS:85016648432

SN - 0885-3185

VL - 32

SP - 510

EP - 525

JO - Movement Disorders

JF - Movement Disorders

IS - 4

ER -